Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a study ...

Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company ...

Home News PR Newswire Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus ...